Overweight and Obesity
Conditions
Keywords
Overweight
Brief summary
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. The study is designed to evaluate the efficacy and tolerability of setmelanotide administered once or twice daily. The study drug (setmelanotide and placebo) will be administered in a blinded fashion.
Interventions
DRUGSetmelanotide
DRUGPlacebo
Sponsors
Rhythm Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Be between the ages of 18 and 65 years, inclusive. * Able to provide voluntary, written informed consent with comprehension of all aspects of the protocol, prior to any study procedures. * In good general health, without significant medical history, physical examination findings, or clinical laboratory abnormalities. * Body Mass Index: 30 to 40 Kg/m2. * Stable body weight by participant report (+/- 5 Kg) during previous 6 months. * Blood pressure (\<140/90 mmHg); may include stable dose (≥ 30 days of use) of up to two anti-hypertensive medications to achieve control and that are intended to remain on a stable dose during the protocol. * Willingness (during screening) and demonstrated ability (as witnessed in the clinic prior to randomization) to self-administer study medication subcutaneously via a once or twice daily SC injection using a small insulin syringe. * Willing to maintain a healthy diet and exercise regime throughout study as recommended by counseling at study start. * Female participants must have negative serum pregnancy test and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method (i.e., sponge), or a double-barrier method of birth control (i.e., condom with spermicide) or abstinence must be used/ practiced throughout the study and for 90 days following the study. * Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or post-menopausal for at least 12 months (and confirmed with a screening FSH level in the post-menopausal lab range), do not require contraception during the study. * Males with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study and for 90 days following the study. Male participants must not donate sperm for 90 days following their participation in the study.
Exclusion criteria
* Fasting blood glucose \> than 140 mg/dL. * TSH level outside the normal range. * Creatinine \> 1.5 times the upper limit of normal. * Liver function tests \> 2 times the upper limit of normal. * Active or history of any significant medical condition including renal, hepatic, pulmonary, gastrointestinal, cardiovascular, genitourinary, endocrine, immunologic, metabolic, neurologic or hematological disease. * Patients with a history of the following: 1. Uncontrolled hypertension; 2. Diabetes requiring medical treatment; 3. Major depressive disorder within the last 2 years; 4. Any lifetime history of a suicide attempt; 5. Any suicidal ideation/behavior in the last month; 6. Other severe psychiatric disorders (e.g. schizophrenia, bipolar disorder, severe eating disorders including bulimia). * A PHQ-9 score of ≥15. * Any suicidal ideation of type 4 or 5 on the C-SSRS. * Prior bariatric surgery. * History or close family history (parents or siblings) of melanoma. * Significant dermatologic findings as part of the Screening comprehensive skin evaluation performed by the dermatologist. * Currently treated with anorectic agents or drugs in last 2 months from screening with anorexia as a frequent side event. * Taking more than 2 anti-hypertensive medications. * Acute illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the patient or obscure interpretation of laboratory test results or interpretation of study data. * History of any malignancy, past or present, including skin cancer, multiple severely dysplastic nevi, or nevoid basal cell carcinoma. * History of HIV infection or Hepatitis B or C. * History of significant drug hypersensitivity or anaphylaxis. * History of hypersensitivity to proteins (e.g., allergy shots). * Any clinically significant abnormalities on screening laboratories as determined by the Investigator. * Abnormal 12-lead electrocardiogram (ECG) at screening, except minor deviations deemed to be of no clinical significance by the Investigator. QTcF must be \< 450 ms. * Received any experimental drugs or devices or have participated in a clinical study within 30 days prior to dosing. * Blood donation greater than 500 mL within 60 days prior to screening or intent to donate up to 30 days after Final Study Visit. * Hospitalization for surgery within the 3 months prior to screening except for minor outpatient procedures, or any planned hospitalizations during the study period. * Poor venous access or inability to tolerate venipuncture. * Inability to attend all study visits or comply with protocol requirements including fasting and restrictions on concomitant medication intake. * Participation in weight loss programs during the study period, including nutritional supplements/ replacements other than as recommended by nutritional counseling provided at study start. * Use of prescription medications on a regular basis with the following exceptions: 1. Contraceptives (must be on for ≥3 months); 2. Hormone replacement therapy (must be on stable dose for ≥3 months); 3. Antihypertensives (\<2 medications on a stable dose for ≥ 30 days); 4. Statins (dose must be ≤ half the maximum dose; must be on a stable dose ≥3 months); 5. Thyroxin (stable dose for ≥ 30 days); 6. The last use of any other prescription medication must have been greater than 5 half-lives for the specific medication or at least 14 days prior to randomization, whichever is longer. * Women who are pregnant or are breast feeding. * Previously randomized and dosed in this study or previously exposed to setmelanotide. * History of alcohol or drug abuse within 5 years of Screening Visit. * Any other reason, which in the opinion of the Investigator, would confound proper evaluation of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With TEAEs - Stage C | From first dose up to Day 114 | An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs. |
| Body Weight - Stage B | Baseline | — |
| Percent Change From Baseline in Body Weight at Week 12 - Stage B | Baseline, Week 12 | — |
| Body Weight - Stage C | Baseline | — |
| Percent Change From Baseline in Body Weight at Week 12 - Stage C | Baseline, Week 12 | — |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A | From first dose up to Day 114 | An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs. |
| Number of Participants With TEAEs - Stage B | From first dose up to Day 114 | An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs. |
| Body Weight - Stage A | Baseline | — |
| Percent Change From Baseline in Body Weight at Week 12 - Stage A | Baseline, Week 12 | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours after dosing on Day 8 | — |
| Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline and for one 24-hour interval between Days 8 or 15 | The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in ABPM parameters (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], pulse pressure, mean arterial pressure \[MAP\]) during 24-hour interval between Days 8 and 15 is presented. |
| Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline and for one 24-hour interval between Days 8 or 15 | The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in ABPM parameters (SBP, DBP, pulse pressure, MAP) during 24-hour interval between Days 8 and 15 is presented. |
| Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline and for one 24-hour interval between Days 8 and 15 | The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented. |
| Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline and for one 24-hour interval between Days 8 and 15 | The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented. |
| Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24 hours after dosing on Day 8 | — |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Stage A: Setmelanotide 0.75 mg BID Participants received setmelanotide 0.75 mg by SC injection BID for approximately 4 weeks while housed in the Phase 1 unit. During the first 4 weeks, participants were advanced to setmelanotide 2 mg SC BID. Thereafter, participants received setmelanotide 2 mg QD by SC injection for the rest of the 12-week study with drug self-administration as outpatients. | 10 |
| Stage A: Setmelanotide 1.5 mg QD Participants received setmelanotide 1.5 mg by SC injection QD for approximately 4 weeks while housed in the Phase 1 unit. During the first 4 weeks, participants were advanced to setmelanotide 2 mg once daily. Thereafter, participants received setmelanotide 2 mg once daily by SC injection for the rest of the 12-week study with drug self-administration as outpatients. | 9 |
| Stage A: Placebo 0.75 mg BID Participants received placebo matched to setmelanotide by SC injection BID for approximately 4 weeks while housed in the Phase 1 unit. Thereafter, participants received placebo matched to setmelanotide QD by SC injection for the rest of the 12-week study with drug self-administration as outpatients. | 3 |
| Stage A: Placebo 1.5 mg QD Participants received placebo matched to setmelanotide by SC injection QD for approximately 4 weeks while housed in the Phase 1 unit. Thereafter, participants received placebo matched to setmelanotide QD by SC injection for the rest of the 12-week study with drug self-administration as outpatients. | 3 |
| Stage B: Setmelanotide 1.5 mg QD Participants initially received setmelanotide 1.5 mg QD and then advanced to 2 mg QD for the remainder of the 12-week treatment period. All participants self-administered the study drug. | 11 |
| Stage B: Placebo 1.5 mg QD Participants received placebo matched to setmelanotide QD for the 12-week treatment period. All participants self-administered the study drug. | 6 |
| Stage C: Setmelanotide 2 mg QD Participants received setmelanotide 2 mg QD for the 12-week treatment period. All participants self-administered the study drug. | 29 |
| Stage C: Placebo 2 mg QD Participants received placebo matched to setmelanotide QD for the 12-week treatment period. All participants self-administered the study drug. | 28 |
| Total | 99 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 0 |
| Overall Study | Unable to comply with study visits | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 3 |
Baseline characteristics
| Characteristic | Total | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage A: Setmelanotide 0.75 mg BID | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 99 Participants | 9 Participants | 3 Participants | 3 Participants | 10 Participants | 11 Participants | 6 Participants | 29 Participants | 28 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 17 Participants | 5 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 3 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 82 Participants | 4 Participants | 1 Participants | 3 Participants | 9 Participants | 10 Participants | 4 Participants | 26 Participants | 25 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 44 Participants | 4 Participants | 1 Participants | 2 Participants | 8 Participants | 5 Participants | 4 Participants | 11 Participants | 9 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 6 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 3 Participants | 2 Participants |
| Race (NIH/OMB) White | 46 Participants | 4 Participants | 1 Participants | 1 Participants | 2 Participants | 6 Participants | 2 Participants | 13 Participants | 17 Participants |
| Region of Enrollment United States | 99 participants | 9 participants | 3 participants | 3 participants | 10 participants | 11 participants | 6 participants | 29 participants | 28 participants |
| Sex: Female, Male Female | 59 Participants | 3 Participants | 1 Participants | 1 Participants | 6 Participants | 5 Participants | 4 Participants | 21 Participants | 18 Participants |
| Sex: Female, Male Male | 40 Participants | 6 Participants | 2 Participants | 2 Participants | 4 Participants | 6 Participants | 2 Participants | 8 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 9 | 0 / 3 | 0 / 3 | 0 / 11 | 0 / 6 | 0 / 29 | 0 / 28 |
| other Total, other adverse events | 10 / 10 | 8 / 9 | 2 / 3 | 3 / 3 | 9 / 11 | 3 / 6 | 29 / 29 | 21 / 28 |
| serious Total, serious adverse events | 0 / 10 | 0 / 9 | 0 / 3 | 0 / 3 | 0 / 11 | 0 / 6 | 1 / 29 | 1 / 28 |
Outcome results
Primary
Body Weight - Stage A
Time frame: Baseline
Population: Full Analysis Set (FAS) included all participants with a baseline and at least one post-dose efficacy observation. Data from 2 placebo groups were combined for the efficacy analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Body Weight - Stage A | 101.7 Kilograms (kg) | Standard Error 5.09 |
| Stage A: Setmelanotide 1.5 mg QD | Body Weight - Stage A | 101.7 Kilograms (kg) | Standard Error 4.24 |
| Stage A: Placebo | Body Weight - Stage A | 94.5 Kilograms (kg) | Standard Error 3.85 |
Primary
Body Weight - Stage B
Time frame: Baseline
Population: Participants in the FAS were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Body Weight - Stage B | 99.4 kg | Standard Error 3.51 |
| Stage A: Setmelanotide 1.5 mg QD | Body Weight - Stage B | 93.3 kg | Standard Error 2.92 |
Primary
Body Weight - Stage C
Time frame: Baseline
Population: Participants in the FAS were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Body Weight - Stage C | 98.5 Kg | Standard Error 1.87 |
| Stage A: Setmelanotide 1.5 mg QD | Body Weight - Stage C | 98.7 Kg | Standard Error 2.44 |
Primary
Number of Participants With TEAEs - Stage B
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
Time frame: From first dose up to Day 114
Population: Safety Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Number of Participants With TEAEs - Stage B | 9 Participants |
| Stage A: Setmelanotide 1.5 mg QD | Number of Participants With TEAEs - Stage B | 3 Participants |
Primary
Number of Participants With TEAEs - Stage C
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
Time frame: From first dose up to Day 114
Population: Safety Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Number of Participants With TEAEs - Stage C | 29 Participants |
| Stage A: Setmelanotide 1.5 mg QD | Number of Participants With TEAEs - Stage C | 21 Participants |
Primary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
Time frame: From first dose up to Day 114
Population: Safety Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A | 10 Participants |
| Stage A: Setmelanotide 1.5 mg QD | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A | 8 Participants |
| Stage A: Placebo | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A | 2 Participants |
| Stage A: Placebo 1.5 mg QD | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A | 3 Participants |
Primary
Percent Change From Baseline in Body Weight at Week 12 - Stage A
Time frame: Baseline, Week 12
Population: Participants in the FAS with available data were analyzed. Data from 2 placebo groups were combined for the efficacy analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Percent Change From Baseline in Body Weight at Week 12 - Stage A | -1.38 percent change |
| Stage A: Setmelanotide 1.5 mg QD | Percent Change From Baseline in Body Weight at Week 12 - Stage A | -0.74 percent change |
| Stage A: Placebo | Percent Change From Baseline in Body Weight at Week 12 - Stage A | 2.89 percent change |
p-value: 0.00490% CI: [-6.81, -1.72]Longitudinal mixed analysis of variance
p-value: 0.01290% CI: [-6.23, -1.03]Longitudinal mixed analysis of variance
Primary
Percent Change From Baseline in Body Weight at Week 12 - Stage B
Time frame: Baseline, Week 12
Population: Participants in the FAS with available data were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Percent Change From Baseline in Body Weight at Week 12 - Stage B | -1.29 percent change |
| Stage A: Setmelanotide 1.5 mg QD | Percent Change From Baseline in Body Weight at Week 12 - Stage B | 2.28 percent change |
p-value: <0.00190% CI: [-5.24, -1.89]Longitudinal mixed analysis of variance
Primary
Percent Change From Baseline in Body Weight at Week 12 - Stage C
Time frame: Baseline, Week 12
Population: Participants in the FAS with available data were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) |
|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Percent Change From Baseline in Body Weight at Week 12 - Stage C | -2.28 percent change |
| Stage A: Setmelanotide 1.5 mg QD | Percent Change From Baseline in Body Weight at Week 12 - Stage C | -0.06 percent change |
p-value: 0.00290% CI: [-3.44, -1]Longitudinal mixed analysis of variance
Secondary
Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in ABPM parameters (SBP, DBP, pulse pressure, MAP) during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 or 15
Population: Participants in the FAS with available data were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: SBP | 117.57 mmHg | Standard Deviation 9.99 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: SBP | 1.63 mmHg | Standard Deviation 6.83 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: DBP | 68.90 mmHg | Standard Deviation 7.57 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: DBP | 1.77 mmHg | Standard Deviation 4.83 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: Pulse pressure | 48.67 mmHg | Standard Deviation 7.46 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: Pulse pressure | -0.14 mmHg | Standard Deviation 3.39 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: MAP | 85.97 mmHg | Standard Deviation 7.33 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: MAP | 1.21 mmHg | Standard Deviation 5.35 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: MAP | 0.68 mmHg | Standard Deviation 4.56 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: SBP | 117.51 mmHg | Standard Deviation 8.05 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: Pulse pressure | 47.59 mmHg | Standard Deviation 7.58 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: SBP | 1.22 mmHg | Standard Deviation 6.28 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: MAP | 86.30 mmHg | Standard Deviation 5.23 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline: DBP | 69.92 mmHg | Standard Deviation 5.96 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: Pulse pressure | 0.38 mmHg | Standard Deviation 2.7 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15: DBP | 0.83 mmHg | Standard Deviation 4.32 |
Secondary
Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in ABPM parameters (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], pulse pressure, mean arterial pressure \[MAP\]) during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 or 15
Population: Participants in the FAS with available data were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: SBP | 121.09 millimeters of mercury (mmHg) | Standard Deviation 7.18 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: SBP | -4.08 millimeters of mercury (mmHg) | Standard Deviation 6.55 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: DBP | 71.02 millimeters of mercury (mmHg) | Standard Deviation 5.03 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: DBP | -2.13 millimeters of mercury (mmHg) | Standard Deviation 3.93 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: Pulse pressure | 50.07 millimeters of mercury (mmHg) | Standard Deviation 4.77 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: Pulse pressure | -1.94 millimeters of mercury (mmHg) | Standard Deviation 3.89 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: MAP | 88.27 millimeters of mercury (mmHg) | Standard Deviation 5.5 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: MAP | -2.73 millimeters of mercury (mmHg) | Standard Deviation 4.42 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: Pulse pressure | -0.68 millimeters of mercury (mmHg) | Standard Deviation 2.32 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: Pulse pressure | 46.79 millimeters of mercury (mmHg) | Standard Deviation 5.31 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: SBP | -2.23 millimeters of mercury (mmHg) | Standard Deviation 3.95 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: MAP | -1.98 millimeters of mercury (mmHg) | Standard Deviation 2.81 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: MAP | 89.05 millimeters of mercury (mmHg) | Standard Deviation 8.69 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: DBP | -1.55 millimeters of mercury (mmHg) | Standard Deviation 2.63 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: DBP | 73.09 millimeters of mercury (mmHg) | Standard Deviation 9.22 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: SBP | 119.89 millimeters of mercury (mmHg) | Standard Deviation 10.36 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: MAP | 85.45 millimeters of mercury (mmHg) | Standard Deviation 2.05 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: DBP | 70.48 millimeters of mercury (mmHg) | Standard Deviation 1.35 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: DBP | 0.58 millimeters of mercury (mmHg) | Standard Deviation 3.42 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: Pulse pressure | 44.83 millimeters of mercury (mmHg) | Standard Deviation 3.2 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: Pulse pressure | -1.25 millimeters of mercury (mmHg) | Standard Deviation 3.1 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: MAP | 0.44 millimeters of mercury (mmHg) | Standard Deviation 3.46 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: SBP | 115.31 millimeters of mercury (mmHg) | Standard Deviation 3.81 |
| Stage A: Placebo | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: SBP | -0.67 millimeters of mercury (mmHg) | Standard Deviation 4.61 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: DBP | 71.08 millimeters of mercury (mmHg) | Standard Deviation 8.81 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: DBP | -1.90 millimeters of mercury (mmHg) | Standard Deviation 2.47 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: SBP | -1.08 millimeters of mercury (mmHg) | Standard Deviation 2.9 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: SBP | 117.01 millimeters of mercury (mmHg) | Standard Deviation 10.09 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: Pulse pressure | 45.93 millimeters of mercury (mmHg) | Standard Deviation 2.07 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: MAP | -1.63 millimeters of mercury (mmHg) | Standard Deviation 2.67 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline: MAP | 86.85 millimeters of mercury (mmHg) | Standard Deviation 8.34 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15: Pulse pressure | 0.82 millimeters of mercury (mmHg) | Standard Deviation 0.77 |
Secondary
Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 and 15
Population: Participants in the FAS with available data were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline | 79.28 beats per minute (bpm) | Standard Deviation 7.05 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15 | -0.90 beats per minute (bpm) | Standard Deviation 3.87 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15 | -2.70 beats per minute (bpm) | Standard Deviation 5.38 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline | 77.55 beats per minute (bpm) | Standard Deviation 8.21 |
| Stage A: Placebo | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline | 72.92 beats per minute (bpm) | Standard Deviation 6.8 |
| Stage A: Placebo | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15 | -5.75 beats per minute (bpm) | Standard Deviation 7.72 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Baseline | 68.10 beats per minute (bpm) | Standard Deviation 6.48 |
| Stage A: Placebo 1.5 mg QD | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A | Change at 24-hour interval between Days 8 and 15 | 1.35 beats per minute (bpm) | Standard Deviation 7.7 |
Secondary
Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 and 15
Population: Participants in the FAS with available data were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline | 80.77 bpm | Standard Deviation 9.03 |
| Stage A: Setmelanotide 0.75 mg BID | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15 | -0.95 bpm | Standard Deviation 9.78 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C | Baseline | 73.01 bpm | Standard Deviation 10.65 |
| Stage A: Setmelanotide 1.5 mg QD | Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C | Change at 24-hour interval between Days 8 and 15 | 0.98 bpm | Standard Deviation 4.21 |
Secondary
Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A
Time frame: Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24 hours after dosing on Day 8
Population: Participants in the Pharmacokinetic (PK) Evaluable Population (included all participants who received at least 1 dose of study drug, had a post-baseline observation and had evaluable plasma concentration-time profiles for setmelanotide) with available data were analyzed
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 2 hours postdose | 10.8 nanograms per milliliter (ng/mL) | Standard Deviation 3.93 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 12 hours postdose | 6.02 nanograms per milliliter (ng/mL) | Standard Deviation 2.49 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 6 hours postdose | 11.8 nanograms per milliliter (ng/mL) | Standard Deviation 5.02 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 14 hours postdose | 10.6 nanograms per milliliter (ng/mL) | Standard Deviation 5.65 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 1 hour postdose | 9.18 nanograms per milliliter (ng/mL) | Standard Deviation 3.04 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 16 hours postdose | 13.6 nanograms per milliliter (ng/mL) | Standard Deviation 6.96 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 8 hours postdose | 9.86 nanograms per milliliter (ng/mL) | Standard Deviation 3.66 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 20 hours postdose | 9.26 nanograms per milliliter (ng/mL) | Standard Deviation 3.86 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 4 hours postdose | 13.9 nanograms per milliliter (ng/mL) | Standard Deviation 5.05 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 22 hours postdose | 7.43 nanograms per milliliter (ng/mL) | Standard Deviation 3.32 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 10 hours postdose | 7.48 nanograms per milliliter (ng/mL) | Standard Deviation 3.18 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 24 hours postdose | 5.74 nanograms per milliliter (ng/mL) | Standard Deviation 2.72 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | Predose (0 hours) | 7.24 nanograms per milliliter (ng/mL) | Standard Deviation 2.52 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 24 hours postdose | 3.58 nanograms per milliliter (ng/mL) | Standard Deviation 0.9 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | Predose (0 hours) | 3.54 nanograms per milliliter (ng/mL) | Standard Deviation 0.949 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 1 hour postdose | 8.51 nanograms per milliliter (ng/mL) | Standard Deviation 3.07 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 2 hours postdose | 13.0 nanograms per milliliter (ng/mL) | Standard Deviation 5.75 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 4 hours postdose | 18.0 nanograms per milliliter (ng/mL) | Standard Deviation 6.26 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 6 hours postdose | 20.6 nanograms per milliliter (ng/mL) | Standard Deviation 5.27 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 8 hours postdose | 19.8 nanograms per milliliter (ng/mL) | Standard Deviation 3.19 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 10 hours postdose | 15.5 nanograms per milliliter (ng/mL) | Standard Deviation 2.46 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 12 hours postdose | 11.1 nanograms per milliliter (ng/mL) | Standard Deviation 1.63 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 14 hours postdose | 9.15 nanograms per milliliter (ng/mL) | Standard Deviation 1.29 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 16 hours postdose | 7.32 nanograms per milliliter (ng/mL) | Standard Deviation 1.15 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 20 hours postdose | 5.23 nanograms per milliliter (ng/mL) | Standard Deviation 0.991 |
| Stage A: Setmelanotide 1.5 mg QD | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A | 22 hours postdose | 4.41 nanograms per milliliter (ng/mL) | Standard Deviation 0.945 |
Secondary
Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C
Time frame: Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours after dosing on Day 8
Population: The PK Evaluable Population
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 1 hour postdose | 12.3 ng/mL | Standard Deviation 3.99 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | Predose (0 hours) | 5.03 ng/mL | Standard Deviation 1.84 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 2 hours postdose | 18.1 ng/mL | Standard Deviation 6.23 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 4 hours postdose | 24.2 ng/mL | Standard Deviation 8.19 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 6 hours postdose | 26.5 ng/mL | Standard Deviation 7.32 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 8 hours postdose | 24.0 ng/mL | Standard Deviation 5.88 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 10 hours postdose | 18.1 ng/mL | Standard Deviation 3.76 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 12 hours postdose | 13.9 ng/mL | Standard Deviation 3.35 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 14 hours postdose | 11.2 ng/mL | Standard Deviation 2.47 |
| Stage A: Setmelanotide 0.75 mg BID | Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C | 24 hours postdose | 4.74 ng/mL | Standard Deviation 1.66 |